Navigation Links
MIT develops thin-film 'micro pharmacy'

CAMBRIDGE, Mass.--A new thin-film coating developed at MIT can deliver controlled drug doses to specific targets in the body following implantation, essentially serving as a micro pharmacy.

The film could eventually be used to deliver drugs for cancer, epilepsy, diabetes and other diseases. It is among the first drug-delivery coatings that can be remotely activated by applying a small electric field.

You can mete out what is needed, exactly when it's needed, in a systematic fashion, said Paula Hammond, the Bayer Professor of Chemical Engineering and senior author of a paper on the work appearing in the Feb. 11 issue of the Proceedings of the National Academy of Sciences.

The film, which is typically about 150 nanometers (billionths of a meter) thick, can be implanted in specific parts of the body.

The films are made from alternating layers of two materials: a negatively charged pigment and a positively charged drug molecule, or a neutral drug wrapped in a positively charged molecule.

The pigment, called Prussian Blue, sandwiches the drug molecules and holds them in place. (Part of the reason the researchers chose to work with Prussian Blue is that the FDA has already found it safe for use in humans.)

When an electrical potential is applied to the film, the Prussian Blue loses its negative charge, which causes the film to disintegrate, releasing the drugs. The amount of drug delivered and the timing of the dose can be precisely controlled by turning the voltage on and off.

The electrical signal can be remotely administered (for example, by a physician) using radio signals or other techniques that have already been developed for other biomedical devices.

The films can carry discrete packets of drugs that can be released separately, which could be especially beneficial for chemotherapy. The research team is now working on loading the films with different cancer drugs.

Eventually, devices could be designed that can automatically deliver drugs after sensing that they're needed. For example, they could release chemotherapy agents if a tumor starts to regrow, or deliver insulin if a diabetic patient has high blood sugar.

You could eventually have a signaling system with biosensors coupled with the drug delivery component, said Daniel Schmidt, a graduate student in chemical engineering and one of the lead authors of the paper.

Other lead authors are recent MIT PhD recipients Kris Wood, now a postdoctoral associate at the Broad Institute of MIT and Harvard, and Nicole Zacharia, now a postdoctoral associate at the University of Toronto.

Because the films are built layer by layer, it is easy to control their composition. They can be coated onto a surface of any size or shape, which offers more design flexibility than other drug-delivery devices that have to be microfabricated.

The drawback to microfabricated devices is that it's hard to coat the drug over a large surface area or over an area that is not planar, said Wood.

Another advantage to the films is that they are easy to mass-produce using a variety of techniques, said Hammond. These thin-film systems can be directly applied or patterned onto 3D surfaces such as medical implants.


Contact: Elizabeth Thomson
Massachusetts Institute of Technology

Related medicine news :

1. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
2. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
3. Silverchair Learning Systems Updates and Develops New Courses
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. UCLA doctor develops new technique to treat varicose veins
6. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
7. Couples more likely to divorce if spouse develops cervical or testicular cancer
8. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
9. Dblur Concludes Licensing Deal With STMicroelectronics
10. Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc.
11. Opportunity Internationals Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology: